Manuscripts and Publications

Filters: Keyword is Female  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
Wilson EC, Iverson E, Garofalo R, Belzer M.  2012.  Parental support and condom use among transgender female youth.. J Assoc Nurses AIDS Care. 23(4):306-17.
Straub DM, Deeds BGriffin, Willard N, Castor J, Peralta L, Francisco VT, Ellen J.  2007.  Partnership selection and formation: a case study of developing adolescent health community-researcher partnerships in fifteen U.S. communities.. J Adolesc Health. 40(6):489-98.
Rudy BJ, Murphy DA, D Harris R, Muenz L, Ellen J.  2009.  Patient-related risks for nonadherence to antiretroviral therapy among HIV-infected youth in the United States: a study of prevalence and interactions.. AIDS Patient Care STDS. 23(3):185-94.
Dempsey AG, Macdonell KE, Naar-King S, Lau C-Y.  2012.  Patterns of disclosure among youth who are HIV-positive: a multisite study.. J Adolesc Health. 50(3):315-7.
Coy KC, Hazen RJ, Kirkham HS, Delpino A, Siegler AJ.  2019.  Persistence on HIV preexposure prophylaxis medication over a 2-year period among a national sample of 7148 PrEP users, United States, 2015 to 2017.. J Int AIDS Soc. 22(2):e25252.
Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani RM, Liu NX, Muenz LR et al..  2008.  Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.. Antimicrob Agents Chemother. 52(2):631-7.
Baheti G, Kiser JJ, Havens PL, Fletcher CV.  2011.  Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients.. Antimicrob Agents Chemother. 55(11):5294-9.
Siegler AJ, C Mehta C, Mouhanna F, Giler RMera, Castel A, Pembleton E, Jaggi C, Jones J, Kramer MR, McGuinness P et al..  2020.  Policy- and county-level associations with HIV pre-exposure prophylaxis use, the United States, 2018.. Ann Epidemiol. 45:24-31.e3.
Gross IMoses, Hosek S, Richards MHeather, M Fernández I.  2016.  Predictors and Profiles of Antiretroviral Therapy Adherence Among African American Adolescents and Young Adult Males Living with HIV.. AIDS Patient Care STDS. 30(7):324-38.
Outlaw AY, Naar-King S, Janisse H, Parsons JT.  2010.  Predictors of condom use in a multisite study of high-risk youth living with HIV.. AIDS Educ Prev. 22(1):1-14.
Macdonell KE, Naar-King S, Murphy DA, Parsons JT, Harper GW.  2010.  Predictors of medication adherence in high risk youth of color living with HIV.. J Pediatr Psychol. 35(6):593-601.
MacDonell KKolmodin, Jacques-Tiura AJ, Naar S, Fernandez MIsabella.  2016.  Predictors of Self-Reported Adherence to Antiretroviral Medication in a Multisite Study of Ethnic and Racial Minority HIV-Positive Youth.. J Pediatr Psychol. 41(4):419-28.
Warren JC, M Fernández I, Harper GW, Hidalgo MA, Jamil OB, Torres RSebastián.  2008.  Predictors of unprotected sex among young sexually active African American, Hispanic, and White MSM: the importance of ethnicity and culture.. AIDS Behav. 12(3):459-68.
Sales JM, Escoffery C, Hussen SA, Haddad LB, McCumber M, Kwiatkowski E, Filipowicz T, Sanchez M, Psioda MA, Sheth AN.  2021.  Pre-exposure Prophylaxis Implementation in Family Planning Services Across the Southern United States: Findings from a Survey Among Staff, Providers and Administrators Working in Title X-Funded Clinics.. AIDS Behav. 25(6):1901-1912.
Gamarel KE, Brown L, Kahler CW, M Fernández I, Bruce D, Nichols S.  2016.  Prevalence and correlates of substance use among youth living with HIV in clinical settings.. Drug Alcohol Depend. 169:11-18.
Rudy BJ, Murphy DA, D Harris R, Muenz L, Ellen J.  2010.  Prevalence and interactions of patient-related risks for nonadherence to antiretroviral therapy among perinatally infected youth in the United States.. AIDS Patient Care STDS. 24(2):97-104.
Kahn JA, Burk RD, Squires KE, Kapogiannis BG, Rudy B, Xu J, Gonin R, Liu N, Worrell C, Wilson CM.  2012.  Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination.. J Acquir Immune Defic Syndr. 61(3):390-9.
Kahn JA, Rudy BJ, Xu J, Kapogiannis B, Secord E, Gillison M.  2016.  Prevalence and risk factors for oral DNA tumor viruses in HIV-infected youth.. J Med Virol. 88(11):1944-52.
Kapogiannis BG, Leister E, Siberry GK, Van Dyke RB, Rudy B, Flynn P, Williams PL.  2016.  Prevalence of and progression to abnormal noninvasive markers of liver disease (aspartate aminotransferase-to-platelet ratio index and Fibrosis-4) among US HIV-infected youth.. AIDS. 30(6):889-98.
Viani RM, Peralta L, Aldrovandi G, Kapogiannis BG, Mitchell R, Spector SA, Lie YS, Weidler JM, Bates MP, Liu N et al..  2006.  Prevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study.. J Infect Dis. 194(11):1505-9.
Aaron KJ, Kempf M-C, Christenson RH, Wilson CM, Muntner P, Shrestha S.  2012.  Prevalence of proteinuria and elevated serum cystatin C among HIV-Infected Adolescents in the Reaching for Excellence in Adolescent Care and Health (REACH) study.. J Acquir Immune Defic Syndr. 61(4):499-506.
Ott MA, Alexander AB, Lally M, Steever JB, Zimet GD.  2013.  Preventive misconception and adolescents' knowledge about HIV vaccine trials.. J Med Ethics. 39(12):765-71.
Coleman CG, Sales JM, Escoffery C, Piper KN, Powell L, Sheth AN.  2021.  Primary Care and Pre-exposure Prophylaxis Services in Publicly Funded Family Planning Clinics in the Southern United States.. J Gen Intern Med. 36(10):2958-2965.
Ludema C, Wilson CM, Lally MA, van den Berg JJ, J Fortenberry D.  2020.  Prior incarceration associated with missed HIV care visits among young people living with HIV in the US.. AIDS Care. 32(9):1150-1154.
M Fernández I, Huszti HC, Wilson PA, Kahana S, Nichols S, Gonin R, Xu J, Kapogiannis BG.  2015.  Profiles of Risk Among HIV-Infected Youth in Clinic Settings.. AIDS Behav. 19(5):918-30.
Reed SJ, Miller RLin, Francisco VT.  2012.  Programmatic capacity and HIV structural change interventions: influences on coalitions' success and efficiency in accomplishing intermediate outcomes.. J Prev Interv Community. 40(2):118-30.
Hosek SG, Harper GW, Lemos D, Burke-Miller J, Lee S, Friedman L, Martinez J.  2018.  Project ACCEPT: Evaluation of a Group-Based Intervention to Improve Engagement in Care for Youth Newly Diagnosed with HIV.. AIDS Behav. 22(8):2650-2661.
M Dolcini M, Harper GW, Boyer CB, Pollack LM.  2010.  Project ORE: A friendship-based intervention to prevent HIV/STI in urban African American adolescent females.. Health Educ Behav. 37(1):115-32.
Brown LK, Whiteley L, Harper GW, Nichols S, Nieves A.  2015.  Psychological symptoms among 2032 youth living with HIV: a multisite study.. AIDS Patient Care STDS. 29(4):212-9.
Naar-King S, Kolmodin K, Parsons JT, Murphy D.  2010.  Psychosocial factors and substance use in high-risk youth living with HIV: a multi-site study.. AIDS Care. 22(4):475-82.
S
Keizur EM, Goldbeck C, Vavala G, Romero-Espinoza A, Ocasio M, Fournier J, Lee S-J, Abdalian S-E, Rotheram MJane, Klausner JD.  2020.  Safety and Effectiveness of Same-Day Chlamydia trachomatis and Neisseria gonorrhoeae Screening and Treatment Among Gay, Bisexual, Transgender, and Homeless Youth in Los Angeles, California, and New Orleans, Louisiana.. Sex Transm Dis. 47(1):19-23.
Boone MR, Cherenack EM, Wilson PA.  2015.  Self-Efficacy for Sexual Risk Reduction and Partner HIV Status as Correlates of Sexual Risk Behavior Among HIV-Positive Adolescent Girls and Women.. AIDS Patient Care STDS. 29(6):346-53.
Havens PL, Mulligan K, Hazra R, Flynn P, Rutledge B, Van Loan MD, Lujan-Zilbermann J, Kapogiannis BG, Wilson CM, Stephensen CB.  2012.  Serum 25-hydroxyvitamin D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infection.. J Clin Endocrinol Metab. 97(11):4004-13.
Wilson EC, Garofalo R, D Harris R, Belzer M.  2010.  Sexual risk taking among transgender male-to-female youths with different partner types.. Am J Public Health. 100(8):1500-5.
Shannon CL, Keizur EM, Fehrenbacher A, Wood-Palmer D, Ramos W, Koussa M, Fournier J, Lee S-J, Patel D, Akabike WN et al..  2019.  Sexually Transmitted Infection Positivity Among Adolescents With or at High-Risk for Human Immunodeficiency Virus Infection in Los Angeles and New Orleans.. Sex Transm Dis. 46(11):737-742.
Mullins TLKowalczy, Li SX, Bethel J, Goodenow MM, Hudey S, Sleasman JW.  2018.  Sexually transmitted infections and immune activation among HIV-infected but virally suppressed youth on antiretroviral therapy.. J Clin Virol. 102:7-11.
Reisner SL, Jadwin-Cakmak L, Sava L, Liu SS, Harper GW.  2019.  Situated Vulnerabilities, Sexual Risk, and Sexually Transmitted Infections' Diagnoses in a Sample of Transgender Youth in the United States.. AIDS Patient Care STDS. 33(3):120-130.
Lee S, Yamazaki M, D Harris R, Harper GW, Ellen J.  2015.  Social Support and Human Immunodeficiency Virus-Status Disclosure to Friends and Family: Implications for Human Immunodeficiency Virus-Positive Youth.. J Adolesc Health. 57(1):73-80.
Williams JC, Zhang X, Karki M, Chi Y-Y, Wallet SM, Rudy BJ, Nichols SL, Goodenow MM, Sleasman JW.  2018.  Soluble CD14, CD163, and CD27 biomarkers distinguish ART-suppressed youth living with HIV from healthy controls.. J Leukoc Biol. 103(4):671-680.
Arayasirikul S, Wilson EC.  2019.  Spilling the T on Trans-Misogyny and Microaggressions: An Intersectional Oppression and Social Process Among Trans Women.. J Homosex. 66(10):1415-1438.
Harper GW, Lemos D, Hosek SG.  2014.  Stigma reduction in adolescents and young adults newly diagnosed with HIV: findings from the Project ACCEPT intervention.. AIDS Patient Care STDS. 28(10):543-54.
Clum GA, Czaplicki L, Andrinopoulos K, Muessig K, Hamvas L, Ellen JM.  2013.  Strategies and outcomes of HIV status disclosure in HIV-positive young women with abuse histories.. AIDS Patient Care STDS. 27(3):191-200.
Martinez J, Lemos D, Hosek S.  2012.  Stressors and sources of support: the perceptions and experiences of newly diagnosed Latino youth living with HIV.. AIDS Patient Care STDS. 26(5):281-90.
Miller RLin, Reed SJ, Chiaramonte D, Strzyzykowski T, Spring H, Acevedo-Polakovich ID, Chutuape K, Cooper-Walker B, Boyer CB, Ellen JM.  2017.  Structural and Community Change Outcomes of the Connect-to-Protect Coalitions: Trials and Triumphs Securing Adolescent Access to HIV Prevention, Testing, and Medical Care.. Am J Community Psychol. 60(1-2):199-214.
Kahana SY, Jenkins RA, Bruce D, Fernandez MI, Hightow-Weidman LB, Bauermeister JA.  2016.  Structural Determinants of Antiretroviral Therapy Use, HIV Care Attendance, and Viral Suppression among Adolescents and Young Adults Living with HIV.. PLoS One. 11(4):e0151106.
Miller RLin, Strzyzykowski T, Lee K-S, Chiaramonte D, Acevedo-Polakovich I, Spring H, Santiago-Rivera O, Boyer CB, Ellen JM.  2018.  Structural Effects on HIV Risk Among Youth: A Multi-level Analysis.. AIDS Behav. 22(11):3451-3467.
Esposito-Smythers C, Brown LK, Wolff J, Xu J, Thornton S, Tidey J.  2014.  Substance abuse treatment for HIV infected young people: an open pilot trial.. J Subst Abuse Treat. 46(2):244-50.
Agwu AL, Bethel J, Hightow-Weidman LB, Sleasman JW, Wilson CM, Rudy B, Kapogiannis BG.  2012.  Substantial multiclass transmitted drug resistance and drug-relevant polymorphisms among treatment-naïve behaviorally HIV-infected youth.. AIDS Patient Care STDS. 26(4):193-6.
Brennan J, Kuhns LM, Johnson AK, Belzer M, Wilson EC, Garofalo R.  2012.  Syndemic theory and HIV-related risk among young transgender women: the role of multiple, co-occurring health problems and social marginalization.. Am J Public Health. 102(9):1751-7.
T
Willard N, Chutuape K, Stewart-Campbell R, Boyer CB, Ellen J.  2015.  Targeting Structural Change for HIV Prevention: A Process and Tool for Community Application.. Health Promot Pract. 16(6):837-48.
Carballo-Diéguez A, Giguere R, Dolezal C, Chen BA, Kahn J, Zimet G, Mabragaña M, Leu C-S, McGowan I.  2012.  "Tell Juliana": acceptability of the candidate microbicide VivaGel® and two placebo gels among ethnically diverse, sexually active young women participating in a phase 1 microbicide study.. AIDS Behav. 16(7):1761-74.
Havens PL, Long D, Schuster GU, Gordon CM, Price G, Wilson CM, Kapogiannis BG, Mulligan K, Stephensen CB.  2018.  Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone.. Antivir Ther. 23(7):623-628.
Kim-Chang JJ, Wilson L, Chan C, Fischer B, Venturi G, Goodenow MM, Aldrovandi G, Weber TJ, Sleasman JW.  2019.  Tenofovir Has Minimal Effect on Biomarkers of Bone Health in Youth with HIV Receiving Initial Antiretroviral Therapy.. AIDS Res Hum Retroviruses. 35(8):746-754.
Gamarel KE, Westfall AO, Lally MA, Hosek S, Wilson CM.  2018.  Tobacco Use and Sustained Viral Suppression in Youth Living with HIV.. AIDS Behav. 22(6):2018-2025.
Harper GW, Jadwin-Cakmak LA, Popoff E, Campbell BAnne, Granderson R, Wesp LM.  2019.  Transgender and Other Gender-Diverse Youth's Progression Through the HIV Continuum of Care: Socioecological System Barriers.. AIDS Patient Care STDS. 33(1):32-43.
Tanner AE, Philbin MM, Duval A, Ellen J, Kapogiannis B, J Fortenberry D.  2016.  Transitioning HIV-Positive Adolescents to Adult Care: Lessons Learned From Twelve Adolescent Medicine Clinics.. J Pediatr Nurs. 31(5):537-43.
H Rendina J, Talan AJ, Cienfuegos-Szalay J, Carter JA, Shalhav O.  2020.  Treatment Is More Than Prevention: Perceived Personal and Social Benefits of Undetectable = Untransmittable Messaging Among Sexual Minority Men Living with HIV. AIDS Patient Care STDS. 34(10):444-451.
V
Giguere R, Carballo-Diéguez A, Ventuneac A, Mabragaña M, Dolezal C, Chen BA, Kahn JA, Zimet GD, McGowan I.  2012.  Variations in microbicide gel acceptability among young women in the USA and Puerto Rico.. Cult Health Sex. 14(2):151-66.
Clum GA, Chung S-E, Ellen JM, Perez LV, Murphy DA, Harper GW, Hamvas L.  2012.  Victimization and sexual risk behavior in young, HIV positive women: exploration of mediators.. AIDS Behav. 16(4):999-1010.
Stephensen CB, Marquis GS, Kruzich LA, Douglas SD, Aldrovandi GM, Wilson CM.  2006.  Vitamin D status in adolescents and young adults with HIV infection.. Am J Clin Nutr. 83(5):1135-41.
Havens PL, Stephensen CB, Hazra R, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR, Van Loan MD et al..  2012.  Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial.. Clin Infect Dis. 54(7):1013-25.
Havens PL, Hazra R, Stephensen CB, Kiser JJ, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR et al..  2014.  Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumarate.. Antivir Ther. 19(6):613-8.
Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, D Harris R et al..  2018.  Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial.. Clin Infect Dis. 66(2):220-228.

Pages